Marieke J Krimphove1,2, Alexander P Cole1, Sean A Fletcher1, Sabrina S Harmouch1, Sebastian Berg1,3, Stuart R Lipsitz4, Maxine Sun1,5, Junaid Nabi1, Paul L Nguyen6, Jim C Hu7, Adam S Kibel1, Toni K Choueiri5, Luis A Kluth2, Quoc-Dien Trinh8. 1. Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 2. Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany. 3. Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. 4. Division of General Internal Medicine and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 6. Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 7. Department of Urology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA. 8. Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. qtrinh@bwh.harvard.edu.
Abstract
BACKGROUND: Racial differences in prostate cancer (PCa) outcomes in the United States may be due to differences in tumor biology and race-based differences in access and treatment. We designed a study to estimate the relative contribution of these factors on Black/White disparities in overall survival (OS) in advanced PCa. METHODS: We identified Black and White men aged ≥ 40 years with metastatic or locally advanced PCa (cN+ cM+ and/or T3/4) between 2004 and 2010 using the National Cancer Database. We employed sequential propensity score weighting procedures to generate simulated cohorts of Black and White patients with equal demographics, access to care, treatment, and tumor characteristics. Adjusted survival analyses were used to compare survival in these simulated cohorts. The changes in relative survival after each weighting procedure were used to infer the contribution of each set of variables on the excess risk of mortality in Blacks. RESULTS: In total, 35,611 men met inclusion criteria, 5927 (16.77%) of whom were Black. Survival was significantly worse for Black men after adjusting for demographics and comorbidities (hazard ratio (HR) 1.27, 95%-confidence interval (95%-CI) 1.2-1.34, p < 0.001). After simulating equal access to care, there was no significant difference in survival between races (HR 1.04, 95%-CI 0.97-1.12, p = 0.276), despite worse tumor characteristics in Blacks. After simulating equal treatment and equivalent tumor characteristics, Black men had a better survival than Whites (HR 0.93, 95%-CI 0.86-1.01, p = 0.071 and HR 0.92, 95%-CI 0.84-1.00, p = 0.043, respectively). Overall, access-related variables explained 84.7% of the excess risk of death in Black men. CONCLUSION: Our analysis of men with advanced PCa revealed worse OS among Blacks. However, when access to care, treatment, and cancer characteristics are accounted for, Black race was associated with better OS. These findings suggest that initiatives to improve access to care may represent an effective tool to reduce disparities in PCa outcomes.
BACKGROUND: Racial differences in prostate cancer (PCa) outcomes in the United States may be due to differences in tumor biology and race-based differences in access and treatment. We designed a study to estimate the relative contribution of these factors on Black/White disparities in overall survival (OS) in advanced PCa. METHODS: We identified Black and White men aged ≥ 40 years with metastatic or locally advanced PCa (cN+ cM+ and/or T3/4) between 2004 and 2010 using the National Cancer Database. We employed sequential propensity score weighting procedures to generate simulated cohorts of Black and White patients with equal demographics, access to care, treatment, and tumor characteristics. Adjusted survival analyses were used to compare survival in these simulated cohorts. The changes in relative survival after each weighting procedure were used to infer the contribution of each set of variables on the excess risk of mortality in Blacks. RESULTS: In total, 35,611 men met inclusion criteria, 5927 (16.77%) of whom were Black. Survival was significantly worse for Black men after adjusting for demographics and comorbidities (hazard ratio (HR) 1.27, 95%-confidence interval (95%-CI) 1.2-1.34, p < 0.001). After simulating equal access to care, there was no significant difference in survival between races (HR 1.04, 95%-CI 0.97-1.12, p = 0.276), despite worse tumor characteristics in Blacks. After simulating equal treatment and equivalent tumor characteristics, Black men had a better survival than Whites (HR 0.93, 95%-CI 0.86-1.01, p = 0.071 and HR 0.92, 95%-CI 0.84-1.00, p = 0.043, respectively). Overall, access-related variables explained 84.7% of the excess risk of death in Black men. CONCLUSION: Our analysis of men with advanced PCa revealed worse OS among Blacks. However, when access to care, treatment, and cancer characteristics are accounted for, Black race was associated with better OS. These findings suggest that initiatives to improve access to care may represent an effective tool to reduce disparities in PCa outcomes.
Authors: Alexander P Cole; Bjoern J Langbein; Francesco Giganti; Fiona M Fennessy; Clare M Tempany; Mark Emberton Journal: Br J Radiol Date: 2021-12-16 Impact factor: 3.039
Authors: Kevin H Kensler; Shivanshu Awasthi; Mohamed Alshalalfa; Bruce J Trock; Stephen J Freedland; Michael R Freeman; Sungyong You; Brandon A Mahal; Robert B Den; Adam P Dicker; R Jeffrey Karnes; Eric A Klein; Priti Lal; Yang Liu; Elai Davicioni; Walter Rayford; Kosj Yamoah; Timothy R Rebbeck Journal: Eur Urol Open Sci Date: 2022-04-26
Authors: Alexander P Cole; Peter Herzog; Hari S Iyer; Maya Marchese; Brandon A Mahal; Stuart R Lipsitz; Joshua Nyambose; Susan T Gershman; Mark Kennedy; Gail Merriam; Timothy R Rebbeck; Quoc-Dien Trinh Journal: Cancer Date: 2021-05-17 Impact factor: 6.921
Authors: Tobias P Seraphin; Walburga Y Joko-Fru; Shyam S Manraj; Eric Chokunonga; Nontuthuzelo I M Somdyala; Anne Korir; Guy N'Da; Anne Finesse; Henry Wabinga; Mathewos Assefa; Freddy Gnangnon; Rolf Hansen; Nathan G Buziba; Biying Liu; Eva J Kantelhardt; Donald M Parkin Journal: Cancer Causes Control Date: 2021-07-10 Impact factor: 2.506